ER status conversion and subsequent treatment: an assessment of negative ER expression detected by 18F-FES PET in metastatic breast cancer patients with ER-positive primary tumors.
Saved in:
| Title: | ER status conversion and subsequent treatment: an assessment of negative ER expression detected by 18F-FES PET in metastatic breast cancer patients with ER-positive primary tumors. |
|---|---|
| Authors: | You S; Department of Breast and Urological Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China., Xie Y; Department of Breast and Urological Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.; Department of Medical Oncology, Zhongshan Hospital Fudan University, Shanghai, China., Ji M; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.; Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, China.; Center for Biomedical Imaging, Fudan University, Shanghai, China.; Shanghai Engineering Research Center of Molecular Imaging Probes, Shanghai, China., Liu C; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.; Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, China.; Center for Biomedical Imaging, Fudan University, Shanghai, China.; Shanghai Engineering Research Center of Molecular Imaging Probes, Shanghai, China., Zhao Y; Department of Breast and Urological Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China., Gong C; Department of Breast and Urological Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China., Hu S; Department of Breast and Urological Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China., Li Y; Department of Breast and Urological Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China., Yang Z; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.; Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, No. 270, Dongan Road, Shanghai 200032, China.; Center for Biomedical Imaging, Fudan University, Shanghai, China.; Shanghai Engineering Research Center of Molecular Imaging Probes, Shanghai, China., Wang B; Department of Breast and Urological Medical Oncology, Fudan University Shanghai Cancer Center, 130 Dongan Road, Xuhui District, Shanghai 200032, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China. |
| Source: | Therapeutic advances in medical oncology [Ther Adv Med Oncol] 2023 Dec 15; Vol. 15, pp. 17588359231216093. Date of Electronic Publication: 2023 Dec 15 (Print Publication: 2023). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Sage Country of Publication: England NLM ID: 101510808 Publication Model: eCollection Cited Medium: Print ISSN: 1758-8340 (Print) Linking ISSN: 17588340 NLM ISO Abbreviation: Ther Adv Med Oncol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1758-8340 |
|---|---|
| DOI: | 10.1177/17588359231216093 |
